Search

Your search keyword '"Cobimetinib"' showing total 17 results
Start Over Descriptor "Cobimetinib" Publication Type Magazines
17 results on '"Cobimetinib"'

1. Research Data from Sheba Medical Center Update Understanding of Breast Cancer (Class Effect Unveiled: PPARg Agonists and MEK Inhibitors in Cancer Cell Differentiation)

Subjects
Drug therapy, Development and progression, Medical centers, Cell differentiation, Cobimetinib, Cancer research, Drug resistance -- Drug therapy -- Development and progression, Breast cancer -- Development and progression -- Drug therapy, Oncology, Experimental, Cancer -- Research
Abstract

2024 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on breast cancer are discussed in a new report. According to news [...]

Published
2024

2. Revolution Medicines reports progress, expansion of combo strategy with RMC-4630

Subjects
AstraZeneca PLC, Drugs, Cobimetinib, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Revolution Medicines (RVMD) reported interim data from the company's ongoing Phase 1b/2 clinical trial evaluating the combination of RMC-4630 and cobimetinib in an oral presentation at the EORTC-NCI-AACR 32nd Symposium [...]

Published
2020

4. Revolution Medicines to present interim fata from Phase 1b/2 trial of RMC-4630

Subjects
Clinical trials, Vemurafenib, Cobimetinib, Business, News, opinion and commentary
Abstract

Revolution Medicines announced that interim data from the company's ongoing Phase 1b/2 clinical trial evaluating the combination of RMC-4630 and cobimetinib will be reported in an oral presentation in a [...]

Published
2020

6. Reports Summarize Non-Langerhans-Cell Histiocytosis Study Results from Giuseppe Giuffre and Co-Researchers (Choroidal involvement in Rosai-Dorfman disease successfully treated with cobimetinib)

Subjects
Lymphatic diseases -- Development and progression, Physical fitness, Langerhans-cell histiocytosis -- Development and progression, Cobimetinib, Biochemistry, Health
Abstract

2020 SEP 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Lymphatic Diseases and Conditions - Non-Langerhans-Cell Histiocytosis. [...]

Published
2020

7. Roche gets US FDA nod for Tecentriq plus Cotellic & Zelboraf to treat BRAF V600 mutation-positive advanced melanoma

Subjects
United States. Food and Drug Administration, Roche Holding AG, Vemurafenib, Atezolizumab, Cobimetinib, Gene mutation -- Genetic aspects, Biotechnology industries -- Genetic aspects, Melanoma -- Genetic aspects -- Drug therapy, Drug approval, Pharmaceuticals and cosmetics industries, Cotellic (Medication), Zelboraf (Medication), Tecentriq (Medication)
Abstract

Roche announced that the US Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The [...]

Published
2020

8. Revolution Medicines begins patient dosing in phase1 trial of RMC-4630 in combo with pembrolizumab to treat solid tumors

Subjects
Sanofi S.A. -- Product development, Drugs -- Product development, Cobimetinib, Tumors, Colorectal cancer, Pembrolizumab, Pharmaceutical industry -- Product development, Cancer patients, Non-small cell lung cancer, Pharmaceuticals and cosmetics industries
Abstract

Revolution Medicines, a clinical-stage oncology company, announced dosing of the first patient in a multicenter phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the companyÇÖs investigational SHP2 inhibitor, [...]

Published
2020

9. Findings from University Hospitals Leuven Broaden Understanding of Adenocarcinoma (Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review)

Subjects
Vemurafenib, Adenocarcinoma -- Genetic aspects, Physical fitness, Cobimetinib, Pancreatic cancer -- Genetic aspects, Gene mutation -- Genetic aspects, Journalistic ethics, Health
Abstract

2020 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Oncology - Adenocarcinoma. According to news reporting [...]

Published
2020

10. DNA repair-based classification of melanoma cell lines reveals an effect of mutations in BRAF and NRAS driver genes on DNA repair capacity

Subjects
Physical fitness, Cancer -- Genetic aspects, Cobimetinib, Genes -- Genetic aspects, Skin cancer -- Genetic aspects, Gene mutation -- Genetic aspects, DNA -- Genetic aspects, Melanoma -- Genetic aspects, Antineoplastic agents, DNA repair -- Genetic aspects, Anopheles, Trametinib, Vemurafenib, Dabrafenib, Obesity, Technology, Skin, Editors, Health
Abstract

2020 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2020

11. Revolution Medicines' clinical-stage SHP2 inhibitor ProgramMulti-cohort phase 1/2 clinical programme of RMC-4630 gets US

Subjects
Cellular proteins -- Intellectual property, Drugs -- Intellectual property, Cobimetinib, Tyrosine, Cancer treatment, Trademarks, Phenols (Class of compounds), Pharmaceuticals and cosmetics industries
Abstract

Revolution Medicines, a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, announced that the United States Patent and Trademark Office has issued US Patent No. [...]

Published
2020

12. Revolution Medicines announces trial exploring RMC-4630 w/ ERK inhibitor

Subjects
Pancreatic cancer, Drugs, Cobimetinib, Cancer treatment, Cancer, Clinical trials, Tumors, Business, News, opinion and commentary
Abstract

Revolution Medicines announced its intention to support the Netherlands Cancer Institute on a combination clinical study targeting two key nodes in the oncogenic RAS signaling pathway and to supply its [...]

Published
2020

13. Revolution Medicines begins phase 1b/2 study of RMC-4630-02 in combo with cobimetinib in patients with relapsed/refracto

Subjects
Vemurafenib, Cobimetinib, Drugs, Tumors, Pharmaceuticals and cosmetics industries, Cotellic (Medication) -- Product development
Abstract

Revolution Medicines, a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, announced dosing of the first patient in an open-label, [...]

Published
2019

14. Data on Solid Cancer Described by Researchers at Dana-Farber Cancer Institute [Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors]

Subjects
Physical fitness, Cancer -- Care and treatment, Cobimetinib, Cancer research, Obesity, Medical research, Tumors, Editors, Health
Abstract

2019 SEP 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Oncology - Solid Cancer is now available. According [...]

Published
2019

15. Data from Flinders University Advance Knowledge in Melanoma (Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma)

Subjects
Cobimetinib, Medical research, Melanoma -- Care and treatment, Antineoplastic agents, Obesity, Vemurafenib, Clinical trials, Cancer metastasis, Editors, Health
Abstract

2019 SEP 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Oncology - Melanoma. According to news reporting [...]

Published
2019

16. Patent Application Titled 'Deuterated Venetoclax' Published Online (USPTO 20190225607)

Subjects
Physical fitness, Cobimetinib, Patient compliance, Obinutuzumab, Antiarrhythmia agents -- Intellectual property, Antineoplastic agents -- Intellectual property, Decitabine, Obesity, Bendamustine, Editors, Health
Abstract

2019 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a [...]

Published
2019

17. Lichenoid dermatitis with checkpoint inhibitor use described

Author

Nogrady, Bianca

Subjects
Vemurafenib, Thyroid diseases -- Care and treatment, Atezolizumab, Cobimetinib, Dermatitis -- Care and treatment, T cells, Genes, Cancer treatment, Carcinoma, Mycoses, Clinical trials, Mycosis fungoides, Health, Health care industry
Abstract

A patient treated with immune checkpoint inhibitor therapy for thyroid carcinoma presented with lichenoid dermatitis that resembled mycosis fungoides and also showed monoclonal T-cell receptor gene rearrangement. A case report [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results